June S Almenoff (June Almenoff)

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 8

Top Topics

Helicobacter Pylori

Endoscopic Submucosal Dissection

Top Venues

The American journal of gastroenterology

Alimentary pharmacology & therapeutics

Journal of pain research

This page only lists publications with an associated author ORCID identifier.

Publications

Colin W Howden, Shailja C Shah, Salil N Pendse, Elliot Offman, June S Almenoff, Kely L Sheldon
Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics (2023)
Colin W Howden, Shailja C Shah, Salil N Pendse, Elliot Offman, June S Almenoff, Kely L Sheldon
Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics (2023)
June S Almenoff
Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens. The American journal of gastroenterology (2023)
June S Almenoff
Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens. The American journal of gastroenterology (2023)
June S Almenoff
Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens. The American journal of gastroenterology (2023)
William D Chey, Darren M Brenner, Brooks D Cash, Martin Hale, Jeremy Adler, Mansi S Jamindar, Carol B Rockett, June S Almenoff, Enoch Bortey, Jeffrey Gudin
Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies. Journal of pain research 16 (2023)
Colin W Howden, Shailja C Shah, Salil N Pendse, Elliot Offman, June S Almenoff, Kely L Sheldon
Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics (2023)
June S Almenoff
Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens. The American journal of gastroenterology (2023)